VistaGen TherapeuticsVTGN
VTGN
About: Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Employees: 45
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
9% more funds holding
Funds holding: 43 [Q2] → 47 (+4) [Q3]
9.69% less ownership
Funds ownership: 66.08% [Q2] → 56.4% (-9.69%) [Q3]
27% less capital invested
Capital invested by funds: $61.6M [Q2] → $45.2M (-$16.4M) [Q3]
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
77% less call options, than puts
Call options by funds: $370K | Put options by funds: $1.64M
Research analyst outlook
We haven’t received any recent analyst ratings for VTGN.
Financial journalist opinion
Neutral
Business Wire
1 month ago
Vistagen to Present at the Stifel 2024 Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. Stifel 2024 Healthcare Conference Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Monday, November 18 at 3:35.
Neutral
Seeking Alpha
1 month ago
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Julian Pino - Stifel Andrew Tsai - Jefferies Myles Minter - William Blair Madison El-Saadi - B. Riley Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call.
Negative
Zacks Investment Research
1 month ago
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago.
Neutral
Business Wire
1 month ago
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. “We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute t.
Neutral
Business Wire
1 month ago
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic.
Neutral
Business Wire
1 month ago
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update.
Neutral
Seeking Alpha
2 months ago
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder
Vistagen's fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one of the two studies, PALISADE-3 and PALISADE-4, to succeed in supporting a filing for marketing approval. VTGN had $108.4M as of June 30, 2024, but increased R&D expenses may accelerate cash burn, and the Company could look to use its at-the-market facility or conduct an offering.
Positive
Zacks Investment Research
2 months ago
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
2 months ago
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join together in New York City on Oc.
Neutral
Business Wire
2 months ago
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in its PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray in U.S. registration-directed Phase 3 development for.
Charts implemented using Lightweight Charts™